United States Drug Patent 4,489,071: Claim Scope, Expiration, and Betamethasone Dipropionate Patent Landscape

U.S. Patent No. 4,489,071 protected a specific oil-in-water topical emulsion containing betamethasone dipropionate, white petrolatum, white wax, sorbitol solution, propylene glycol, low-HLB emulsifiers, preservative, buffer, water, and, in dependent claims, cyclomethicone. The patent issued in 1984 and expired no later than December 18, 2001, based on the 17-year term applicable to most pre-Uruguay Round patents. It therefore creates no current U.S. patent barrier to generic manufacture or sale.

The patent’s historical value was formulation-specific rather than molecule-specific. It did not claim betamethasone dipropionate generally, all topical corticosteroid products, or every cream containing the active ingredient. Its strongest claims required a narrow combination of excipient classes, concentration ranges, emulsion characteristics, pH controls, and preservative requirements.

What does U.S. Patent 4,489,071 cover?

U.S. Patent 4,489,071 covers topical anti-inflammatory compositions containing betamethasone dipropionate at 0.02% to 0.1% by weight in a buffered emulsion system. The independent claim requires all nine elements of claim 1:

Element	Required feature in claim 1
Active ingredient	0.02% to 0.1% betamethasone dipropionate
Petrolatum	15% to 40% white petrolatum
Wax	3% to 15% white wax
Sorbitol	5% to 25% of a 70% sorbitol-in-water solution
Propylene glycol	2.5% to 15%
Buffer	Maintains pH at 3 to 6
Emulsifiers	At least one hydrophilic and one lipophilic emulsifier
Emulsifier HLB	2 to 8
Preservative and vehicle	Dermatologically acceptable preservative and water

The claim is composition-based. It does not require a particular manufacturing sequence, package, dosing regimen, disease indication, or clinical result beyond the stated treatment of inflammation.

The claim also uses functional language. The emulsifiers must be sufficient to stabilize the emulsion and disperse betamethasone dipropionate. The preservative must be sufficient to prevent microbial degradation. Those limitations would likely be evaluated through formulation testing, microbiological testing, and ordinary pharmaceutical formulation evidence.

How narrow is claim 1 of patent 4,489,071?

Claim 1 is narrower than a basic active-ingredient claim but broader than the specific formulations in claims 5 through 8.

A product would need to satisfy each required limitation. A formulation could avoid literal infringement by:

omitting white wax;
using a different petroleum phase;
reducing or increasing an excipient outside the claimed range;
using an emulsifier system with an HLB outside 2 to 8;
failing to include both hydrophilic and lipophilic emulsifiers;
using a pH outside 3 to 6;
replacing the 70% sorbitol solution with another humectant system;
using a different preservative system; or
omitting water, if the resulting product were not an aqueous composition.

The ranges are material. For example, a formulation containing 14% white wax would fall within the white-wax limitation, while a formulation containing 16% would not. The doctrine of equivalents could create residual risk for insubstantial changes, but the prosecution history would be important in assessing whether particular range limits were surrendered during examination.

The claim does not require cyclomethicone. Cyclomethicone is added only in claims 3 through 8. A product meeting claim 1 but excluding cyclomethicone could still fall within claim 1.

What do dependent claims 2 through 8 protect?

Claims 2 through 8 progressively narrow the formulation.

Claim	Additional limitations
2	Petrolatum 20% to 30%; white wax 7% to 12%; sorbitol solution 10% to 20%; propylene glycol 3% to 8%; emulsifier HLB 4 to 6
3	Claim 2 plus 3% to 15% cyclomethicone
4	Claim 1 plus 3% to 15% cyclomethicone
5	Specific formulation with 25% petrolatum, 10% white wax, 15% sorbitol solution, 5% propylene glycol, 7% cyclomethicone, ceteth 20, glycerol oleate, phosphate buffer, and 4-chloro-m-cresol
6	Specific formulation with 30% petrolatum, 7% white wax, 15% sorbitol solution, 5% propylene glycol, 5% cyclomethicone, citrate buffer, ceteth 20, glyceryl oleate, and 4-chloro-m-cresol
7	Specific formulation with 20% petrolatum, 10% white wax, 15% sorbitol solution, 5% propylene glycol, 10% cyclomethicone, phosphate buffer, glycerol oleate, and benzyl alcohol
8	Specific formulation with 30% petrolatum, 5% white wax, 10% sorbitol solution, 5% propylene glycol, 5% cyclomethicone, polysorbate 60, sorbitan sesquioleate, phosphate buffer, and 4-chloro-m-cresol

Claims 5 through 8 are highly formulation-specific. Their practical historical significance depended on whether a commercial product used one of those exact compositions or a formulation sufficiently close to it.

Claim 8 differs materially in emulsifier selection from claims 5 through 7. It uses polysorbate 60 and sorbitan sesquioleate rather than ceteth 20 and glycerol or glyceryl oleate. The claim therefore illustrates that the patent sought to protect multiple emulsifier architectures within the same petrolatum-wax-humectant platform.

What is the scope of the 0.06% betamethasone dipropionate limitation?

The 0.06% concentration in claims 5 through 8 is consistent with conventional labeling of betamethasone dipropionate products at approximately 0.05% betamethasone equivalent. Betamethasone dipropionate has a molecular-weight relationship that causes the salt or ester concentration to differ from the labeled betamethasone potency.

The patent claims the stated composition concentration, not merely the therapeutic potency. A product labeled 0.05% betamethasone dipropionate should not automatically be treated as satisfying a claim requiring 0.06% by weight. The actual certificate of analysis, formulation record, and applicable concentration tolerance would control infringement analysis.

When did U.S. Patent 4,489,071 expire?

The patent issued on December 18, 1984. Because it belongs to the pre-Uruguay Round patent class, the default term was generally 17 years from issuance rather than 20 years from the earliest effective nonprovisional filing date. On that basis, the patent expired on December 18, 2001, absent an unusual term adjustment or enforceable extension.

Event	Date or status
Patent	U.S. Patent No. 4,489,071
Issue date	December 18, 1984
Statutory term framework	Generally 17 years from issue for this patent class
Expected expiration	December 18, 2001
Current enforceability	Expired
Current Paragraph IV relevance	None for this patent
Current injunction risk	None based on this expired patent

The patent cannot presently support an injunction against a generic product. It also cannot support a current damages claim for post-expiration conduct.

What was the historical strength of the patent estate?

The patent estate appears to have been concentrated in a single formulation patent rather than distributed across a large family of composition, method-of-use, manufacturing, and delivery patents.

Its historical strengths were:

A defined multi-phase vehicle.
Several nested concentration ranges.
Functional requirements for emulsion stability and active dispersion.
Multiple dependent formulations with cyclomethicone.
Narrow claims that could potentially map to a branded cream formula.

Its weaknesses were:

Expiration in 2001.
No apparent claim to betamethasone dipropionate as a chemical entity.
No claim to all topical dosage forms.
No claim to a broad method of treating dermatitis independent of the formulation.
Numerous design-around opportunities involving waxes, humectants, emulsifiers, preservatives, pH, and silicone content.
Potential written-description, enablement, indefiniteness, and claim-construction issues surrounding “sufficient amounts,” “stabilize,” “disperse,” and HLB measurement methodology.

The patent was therefore stronger against a close-copy cream than against a technically differentiated generic formulation.

What is the Orange Book status of patent 4,489,071?

Patent 4,489,071 has no current Orange Book blocking effect because it expired more than two decades ago. Orange Book-listed patents can affect abbreviated new drug application timing only while they remain legally relevant to the listed drug. An expired formulation patent does not create a current 30-month stay or delay under the Hatch-Waxman framework.

For small-molecule topical products, Orange Book analysis normally separates:

drug-substance patents;
drug-product or formulation patents;
method-of-use patents;
pediatric exclusivity;
regulatory exclusivity; and
patent listing and delisting status.

Patent 4,489,071 falls within the formulation category. It is not a biologic patent and does not create biosimilar litigation exposure under the Biologics Price Competition and Innovation Act.

The FDA Orange Book should be reviewed for any later, separately listed patents associated with a particular betamethasone dipropionate reference product. Those later patents would need independent analysis because they are not automatically covered by the scope of patent 4,489,071. (U.S. Food and Drug Administration, n.d.-a)

What Paragraph IV challenges or litigation affected this patent?

An expired patent cannot presently be the subject of a meaningful Paragraph IV launch challenge. Any Paragraph IV certification directed to patent 4,489,071 would be commercially moot unless the certification arose during the patent’s active term.

The supplied record does not establish a specific infringement action, ANDA litigation proceeding, settlement agreement, or covenant not to sue involving this patent. No litigation conclusion should be attributed to the patent without a docket-level record from PACER, the district courts, or the Federal Circuit.

The relevant legal issue historically would have been whether a generic topical formulation satisfied every limitation of claim 1 or one of the narrower dependent claims. A generic applicant could have used a Paragraph IV certification if the patent were listed and unexpired, arguing invalidity, unenforceability, or noninfringement. A Section viii statement would have been relevant only to an approved method-of-use patent, not to a formulation claim of this type.

What generic entry risks remain for betamethasone dipropionate products?

Patent 4,489,071 presents no current generic-entry risk. Current risk analysis must focus on other rights and regulatory requirements.

Formulation and product-development risks

A generic manufacturer still must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the FDA’s applicable topical-product pathway. Topical corticosteroid products can raise issues involving:

active-ingredient sameness;
dosage-form sameness;
viscosity and rheology;
particle size and crystal form;
emulsion droplet size;
preservative effectiveness;
microbial limits;
release rate;
permeation;
local pharmacodynamic response; and
comparative clinical or dermatopharmacokinetic testing.

Those factors are regulatory and technical barriers, not surviving rights under patent 4,489,071.

Manufacturing and trade-secret barriers

The patent discloses formulation ingredients and ranges, but it does not necessarily disclose every commercially important manufacturing parameter. Mixing order, temperature, homogenization, cooling profile, active dispersion, and preservative incorporation could remain protected as know-how if maintained as trade secrets. Trade-secret rights do not prevent independent development of the same process from publicly available information.

Biosimilar risk

Biosimilar risk is inapplicable. Betamethasone dipropionate is a chemically synthesized small molecule, not a therapeutic biologic. Competitive entry occurs through ANDAs or other small-molecule pathways rather than biosimilar applications.

How does patent 4,489,071 compare with a modern generic patent strategy?

A modern generic manufacturer would usually avoid reliance on the expired patent and design around its narrow formulation limitations. The most direct strategies would include:

Design-around category	Potential approach
Oil phase	Replace or alter white petrolatum and white-wax levels
Humectant	Use a different humectant or a different sorbitol concentration
Emulsifier	Select a different emulsifier pair or HLB profile
Silicone	Exclude cyclomethicone or use another volatile silicone
Buffer	Use a pH system outside the claimed range where product quality permits
Preservative	Use a different preservative system
Active concentration	Use the approved labeled concentration without reproducing claimed ranges
Vehicle	Develop an ointment, lotion, gel, solution, aerosol, or foam rather than the claimed emulsion

A product could still be challenged under the doctrine of equivalents if it made only insubstantial substitutions. That risk is now theoretical for this patent because the patent has expired.

What geographic rights did patent 4,489,071 provide?

The patent provided rights only in the United States. A U.S. patent does not establish protection in Canada, Europe, Japan, China, or other jurisdictions. Foreign counterparts would require separate patent numbers, jurisdictions, filing dates, legal-status records, and expiration analysis.

A global freedom-to-operate review would therefore need to examine:

foreign family members;
national-phase filings;
continuation and divisional applications;
terminal disclaimers;
supplementary protection certificates;
pediatric extensions;
regulatory exclusivity; and
country-specific generic litigation.

The information supplied establishes a U.S. claim set, not a worldwide patent estate.

Key Takeaways

U.S. Patent 4,489,071 claims a betamethasone dipropionate topical emulsion, not the active ingredient generally.
Claim 1 requires specific ranges for white petrolatum, white wax, sorbitol solution, propylene glycol, pH, emulsifier HLB, preservative, and water.
Claims 3 through 8 add cyclomethicone or identify narrow example formulations.
The patent’s strongest historical position was against close-copy creams using the disclosed excipient architecture.
Its main weaknesses were narrow composition requirements and multiple design-around routes.
The patent issued December 18, 1984 and expired no later than December 18, 2001 under the applicable pre-URAA term framework.
It has no current Orange Book blocking effect and no current Paragraph IV significance.
Biosimilar analysis does not apply because betamethasone dipropionate is a small-molecule drug.
Current competitive risk depends on later patents, FDA product requirements, formulation know-how, and market execution rather than patent 4,489,071.

FAQs about U.S. Patent 4,489,071 and betamethasone dipropionate

Can a company still infringe U.S. Patent 4,489,071?

No actionable U.S. infringement liability remains after expiration. The patent may still be relevant for historical analysis, prosecution research, or technical prior-art review.

Does patent 4,489,071 cover betamethasone dipropionate ointment?

Not broadly. The claims require an aqueous composition with specified emulsion components. A conventional anhydrous ointment would generally not satisfy the complete claim structure.

Does using 0.05% betamethasone dipropionate avoid claims requiring 0.06%?

Not automatically. The product’s actual composition and applicable concentration tolerance would determine whether it falls within the claimed range. Label strength alone is not conclusive.

Could cyclomethicone create a separate patent risk?

Cyclomethicone creates no risk under the expired patent. Historically, it was relevant only to dependent claims 3 through 8, which required additional concentration and vehicle limitations.

Is patent 4,489,071 a method-of-use patent?

No. Its claims are directed to compositions. The treatment-of-inflammation language describes the intended use but does not convert the claims into broad method-of-treatment claims.

References

Schering Corporation. (1984). Topical pharmaceutical composition containing betamethasone dipropionate, U.S. Patent No. 4,489,071. U.S. Patent and Trademark Office.

U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	44462	⤷ Start Trial
Australia	3598084	⤷ Start Trial
Australia	565947	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,489,071

Summary for Patent: 4,489,071